Adents, which specializes in developing serialization and traceability software, has concluded a round of funding of €12 million, raising the total amount invested in the company over the last 18 months to €20m. The funding has come from Adents’ existing investors, Naxicap, Omnes Capital and CapHorn Invest.
Adents will use the additional funding for further development of a global network of solution partners and to help it gain footholds in new international markets, particularly the Middle East and Asia.
Track and trace serialization has become a hot topic with many regulatory bodies now insisting on its use to cut down on the use of counterfeit medicines. It’s mandatory in the US by the end of 2017 through the Drug Supply Chain Security Act and in the European Union by the beginning of 2019 through the EU Falsified Medicines Directive.
The Adents Pharma Suite is fully configurable serialization software. Combining it with a global network can help secure implementation lead times up to 5 times faster than other solutions, and enables drug manufacturers to address all current and emerging regulatory requirements pertaining to drug serialization. To date, more than 2 billion unique codes have already been generated and managed globally using Adents software.

Leave a Reply